Sign in
Active, not recruitingPhase 1/2

A Phase I/II Study of VTX-801 in Adult Patients With Wilson's Disease

Key facts

Who runs it
Vivet Therapeutics SAS
Where
Ann Arbor, Dallas, New Haven, Orlando, Sacramento, and Winston-Salem, United StatesSee the 6 sitesAlso in 3 other countries, 4 sites
Status
Active, not recruiting
Phase
Phase 1/2
People taking part
4 people enrolled
Started
3 Sept 2021
Expected to end
18 Jun 2029
Type of study
Interventional
Treatments tested
  • VTX-801
Record updated
30 January 2026

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 18 criteriaShow less

Other criteria

  • Main Inclusion Criteria:
  • Male or female aged 18 and 65 years inclusive
  • Confirmed diagnosis of WD
  • Treated for WD according to international recommendations with no current evidence for inadequate treatment
  • Stable WD for ≥ 1 year, defined as: (i) No significant change in neurologic examination and in status of mood disorder and (ii) Stable laboratory parameters used to assess copper metabolism; Main Exclusion Criteria:
  • ALT level ≥ 2 ULN that is not readily explained by extrinsic factors
  • Total bilirubin > 1.5 x ULN in the absence of proven Gilbert's syndrome; in case of Gilbert's syndrome, direct bilirubin > ULN
  • INR > 1.2
  • Any signs of liver cirrhosis decompensation, including gastrointestinal bleed within 6 months (24 weeks) prior to screening/enrollment visit
  • Patient has moderate or severe renal impairment defined as eGFR CKD-EPI < 60 mL/min/1.73 m2, or patient has nephritis or nephrotic syndrome
  • Any history or current evidence of HIV-1, HIV-2, HTLV 1, or HTLV-2 infection
  • Any history or current evidence of hepatitis B infection
  • Any history of hepatitis C infection, unless previous viral RNA assays in two samples, collected at least 6 months apart, are negative
  • Positive QuantiFERON®-TB Gold tuberculosis test result
  • Any concomitant disorder/condition - including hepatic disorders - or treatment possibly interfering with the conduct or evaluation of the study
  • Any history of diabetes
  • Pregnancy or breastfeeding
  • Body Mass Index ≥ 35 kg/m2; Other protocol defined Inclusion/ Exclusion criteria may apply

Where in United States

Also in 3 other countries, 4 sites

  • University of Michigan Health SystemAnn Arbor, United States
  • University of Texas Southwestern Medical CenterDallas, United States
  • Yale University School of MedecineNew Haven, United States
  • Advent HealthOrlando, United States
  • UC Davis Medical CenterSacramento, United States
  • Wake Forest School of MedicineWinston-Salem, United States

About the trial

What the trial wants to find out

The objectives of this clinical trial are to assess, for up to 5 years, the safety, tolerability and pharmacological activity of a single ascending doses of VTX-801, a gene therapy, administered intravenously (IV) to adult patients with Wilson's Disease prior to and following background WD therapy withdrawal.

The group in the trial

  • VTX-801Treatment being tested

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
A Phase I/II, Multicenter, Non-randomized, Open Label, Adaptive Design, 5-year Follow-up, Single Dose-escalation Study of VTX-801 in Adult Patients With Wilson's Disease
Record updated
30 January 2026